# US 2024/0003897 A1 · Self-contained system, apparatus and method for continuous isolation of extracellular vesicles.

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0003897 A1
- Document ID: US20240003897A1
- Status: Published application
- Kind: A1
- Application number: 18/217,903
- Filed: 2023-07-03
- Published: 2024-01-04
- Earliest claimed: 2022-07-02
- Inventors: Ahmed Fadiel-Metwaly; Adam Koster
- Web page: https://patentgrep.com/patent/US20240003897A1

## CPC

- G01N 33/6842: {Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins}
- B01L 3/502753: {characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation}
- B01L 3/502761: {specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads or physically stretching molecules}
- G01N 1/4077: {by other techniques involving separation of suspended solids}
- G01N 33/54326: {Magnetic particles}
- G01N 33/54386: {Analytical elements}
- B01L 2200/0652: Sorting or classification of particles or molecules
- B01L 2200/0668: Trapping microscopic beads
- B01L 2300/0654: Lenses; Optical fibres
- B01L 2300/0681: Filter
- B01L 2400/043: magnetic forces
- B01L 2400/0487: fluid pressure, pneumatics
- G01N 2001/4088: {filtration}
- G01N 2570/00: Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE

## Abstract

Disclosed is a method for continuous isolation of extracellular vesicles from a biological sample. The method involves filtering the biological sample to obtain a first filtrate of a first predetermined range of particle size, then filtering the first filtrate to obtain a second filtrate of a second predetermined range of particle size, and further filtering the second filtrate to obtain a third filtrate of a third predetermined range of particle size. The third filtrate is mixed with an antibody coated solid substrate to form extracellular vesicles-antibodies conjugate. The extracellular vesicles-antibodies conjugate is isolated from the third filtrate, and selected extracellular vesicles-antibodies conjugate are eluted.

## Claims

### Claim 1

An apparatus for continuous isolation of extracellular vesicles from a biological sample comprising:
a) a separation unit, wherein the separation unit is adapted to be agitated in a predefined agitation pattern, the separation unit comprising:
b) a first filtration unit adapted to filter the biological sample to obtain a first filtrate of a first predetermined range of particle size;
c) a second filtration unit adapted to filter the first filtrate to obtain a second filtrate of a second predetermined range of particle size; and
d) a third filtration unit adapted to filter the second filtrate to obtain a third filtrate of a third predetermined range of particle size;
e) an immunoprecipitation unit adapted to mix the third filtrate with an antibody coated solid substrate to form extracellular vesicles-antibodies conjugate and isolate the extracellular vesicles-antibodies conjugate from the third filtrate; and
f) an elution unit adapted to enable selection and elution of the extracellular vesicles-antibodies conjugate from the apparatus.

### Claim 2 (depends on 1)

The apparatus of claim 1, wherein the elution unit comprises a detection unit adapted to characterize extracellular vesicles for selection from the extracellular vesicles-antibodies conjugate based on a detection parameter.

### Claim 3 (depends on 2)

The apparatus of claim 2, wherein the detection parameter includes at least one of a size of extracellular vesicles, a specificity of extracellular vesicles, or a specificity of antibody in the extracellular vesicles-antibodies conjugate.

### Claim 4 (depends on 1)

The apparatus of claim 1, wherein the solid substrate comprises magnetic nanoparticles, and wherein the material property of the magnetic nanoparticles is at least one of ferromagnetic, ferrimagnetic, paramagnetic, or antiferrimagnetic.

### Claim 5 (depends on 1)

The apparatus of claim 1, wherein the immunoprecipitation unit isolates the extracellular vesicles-antibodies conjugate from the third filtrate based on electromagnetic separation.

### Claim 6 (depends on 1)

The apparatus of claim 1, further comprising a vacuum based pressurized tube adapted to provide the pressurized biological sample to the separation unit.

### Claim 7 (depends on 1)

The apparatus of claim 1, wherein the agitation includes at least one of oscillation, whirlpool, spinning, swirling, or acoustics agitation forms.

### Claim 8 (depends on 1)

The apparatus of claim 1, wherein the predefined agitation pattern includes agitation of at least one or a combination of the first filtration unit, the second filtration unit, and the third filtration unit.

### Claim 9 (depends on 1)

The apparatus of claim 1, wherein the first filtration unit is magnetically attached to the second filtration unit, and the second filtration unit is magnetically attached to the third filtration unit.

### Claim 10 (depends on 1)

The apparatus of claim 1, wherein the first predetermined range of particle size is less than 500 nanometers, the second predetermined range of particle size between 150 nanometers and 500 nanometers, and the third predetermined range of particle size is less than 150 nanometers.

### Claim 11

A method for continuous isolation of extracellular vesicles from a biological sample comprising:
a) filtering the biological sample to obtain a first filtrate of a first predetermined range of particle size;
b) filtering the first filtrate to obtain a second filtrate of a second predetermined range of particle size;
c) filtering the second filtrate to obtain a third filtrate of a third predetermined range of particle size;
d) mixing the third filtrate with an antibody coated solid substrate to form extracellular vesicles-antibodies conjugate;
e) isolating the extracellular vesicles-antibodies conjugate from the third filtrate; and
f) selecting and eluting of the extracellular vesicles-antibodies conjugate.

### Claim 12 (depends on 11)

The method of claim 11, further comprising characterization of extracellular vesicles for the selection of extracellular vesicles from the extracellular vesicles-antibodies conjugate based on a detection parameter.

### Claim 13 (depends on 12)

The method of claim 12, wherein the detection parameter includes at least one of a size of extracellular vesicles, a specificity of extracellular vesicles, or a specificity of antibody in the extracellular vesicles-antibodies conjugate.

### Claim 14 (depends on 11)

The method of claim 11, wherein the solid substrate comprises magnetic nanoparticles, and wherein the material property of the magnetic nanoparticles is at least one of ferromagnetic, ferrimagnetic, paramagnetic, or antiferrimagnetic.

### Claim 15 (depends on 11)

The method of claim 11, wherein the isolating comprises electromagnetic separation of the extracellular vesicles-antibodies conjugate from the third filtrate.

### Claim 16 (depends on 11)

The method of claim 11, wherein the biological sample is pressurized.

### Claim 17 (depends on 1)

The method of claim 1, further comprising agitating at least one of the first filtrate, the second filtrate, or the third filtrate during filtration.

### Claim 18 (depends on 17)

The method of claim 17, wherein the agitation include at least one of oscillation, whirlpool, spinning, swirling, or acoustics agitation forms.

### Claim 19 (depends on 11)

The method of claim 11, wherein the selecting comprises labeling the extracellular vesicles-antibodies conjugate.

### Claim 20 (depends on 11)

The method of claim 11, wherein the first predetermined range of particle size is less than 500 nanometers, the second predetermined range of particle size between 150 nanometers and 500 nanometers, and the third predetermined range of particle size is less than 150 nanometers.
